Transcode Therapeutics (RNAZ) closed at $1.35 on November 18, 2026, down 4.6% from the previous close, on volume of 17,881 shares (30-day average 28,168).
Data as of November 18, 2026.
PRNewswire (Wed, 28-Oct 4:31 PM ET)
TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026
PRNewswire (Mon, 26-Oct 7:31 AM ET)
TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026
PRNewswire (Mon, 19-Oct 8:05 AM ET)
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
Business Wire (Tue, 13-Oct 7:30 AM ET)
PRNewswire (Mon, 28-Sep 8:05 AM ET)
PRNewswire (Tue, 22-Sep 8:04 AM ET)
TransCode Therapeutics Announces Leadership Transition
PRNewswire (Thu, 10-Sep 4:10 PM ET)
PRNewswire (Mon, 31-Aug 8:05 AM ET)
Market Chameleon (Thu, 5-Feb 3:34 AM ET)
Market Chameleon (Wed, 8-Oct 6:50 AM ET)
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
Transcode Therapeutics trades on the NASDAQ stock market under the symbol RNAZ.
As of November 18, 2026, RNAZ stock price declined to $1.35 with 17,881 million shares trading.
RNAZ has a beta of 0.67, meaning it tends to be less sensitive to market movements. RNAZ has a correlation of 0.01 to the broad based SPY ETF.
RNAZ has a market cap of $23.27 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, RNAZ traded as high as $17,245.55 and as low as $1.28.
The top ETF exchange traded funds that RNAZ belongs to (by Net Assets): VXF.
RNAZ has underperformed the market in the last year with a price return of -85.7% while the SPY ETF gained +10.8%. RNAZ has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -57.4% and -14.3%, respectively, while the SPY returned -5.3% and -3.2%, respectively.
RNAZ support price is $1.29 and resistance is $1.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RNAZ shares will trade within this expected range on the day.